Brokerages predict that Johnson & Johnson (NYSE:JNJ) will report earnings per share of $1.79 for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Johnson & Johnson’s earnings. The highest EPS estimate is $1.83 and the lowest is $1.76. Johnson & Johnson reported earnings per share of $1.74 in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.9%. The firm is expected to announce its next quarterly earnings results before the market opens on Tuesday, July 18th.

According to Zacks, analysts expect that Johnson & Johnson will report full-year earnings of $7.10 per share for the current financial year, with EPS estimates ranging from $7.05 to $7.16. For the next year, analysts forecast that the business will report earnings of $7.72 per share, with EPS estimates ranging from $7.47 to $7.95. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.06. Johnson & Johnson had a net margin of 22.87% and a return on equity of 26.50%. The business had revenue of $17.77 billion during the quarter, compared to analysts’ expectations of $18.02 billion. During the same period last year, the company posted $1.68 EPS. The business’s revenue was up 1.6% on a year-over-year basis.

JNJ has been the subject of several research analyst reports. J P Morgan Chase & Co raised shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $123.64 to $140.00 in a research note on Monday, May 15th. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 target price for the company. in a research note on Monday, May 15th. BTIG Research reaffirmed a “hold” rating on shares of Johnson & Johnson in a research note on Wednesday, April 19th. Cowen and Company reaffirmed a “buy” rating and set a $143.00 target price (up previously from $138.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $135.00 target price (up previously from $130.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $133.52.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/09/johnson-johnson-jnj-expected-to-announce-earnings-of-1-79-per-share-updated-updated-updated.html.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.56% during trading on Friday, hitting $132.60. 4,383,105 shares of the company’s stock were exchanged. The company has a market cap of $357.20 billion, a P/E ratio of 22.29 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.00. The company has a 50-day moving average of $130.42 and a 200-day moving average of $122.68.

A number of hedge funds have recently modified their holdings of the stock. Artisan Partners Limited Partnership boosted its stake in shares of Johnson & Johnson by 3.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,554,500 shares of the company’s stock valued at $409,514,000 after buying an additional 127,662 shares during the period. Cleararc Capital Inc. boosted its stake in shares of Johnson & Johnson by 1.1% in the fourth quarter. Cleararc Capital Inc. now owns 74,290 shares of the company’s stock valued at $8,559,000 after buying an additional 825 shares during the period. State Street Corp boosted its stake in shares of Johnson & Johnson by 3.3% in the fourth quarter. State Street Corp now owns 153,566,950 shares of the company’s stock valued at $17,692,455,000 after buying an additional 4,892,277 shares during the period. Horizon Investments LLC boosted its stake in shares of Johnson & Johnson by 92.8% in the fourth quarter. Horizon Investments LLC now owns 25,643 shares of the company’s stock valued at $2,955,000 after buying an additional 12,342 shares during the period. Finally, Northwest Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $336,000. 66.01% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.